Molecure (WAR:MOC) OCF Margin %: 0.00% (As of Sep. 2025)


WAR:MOC Molecure SA WAR:MOC
29 GF Score
Price zł5.38
! 3 Warning Signs
View Full Analysis

What is Molecure OCF Margin %?

Molecure WAR:MOC -1.47% 29 OCF Margin % is 0.00% as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Molecure ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Molecure's Cash Flow from Operations for the three months ended in Sep. 2025 was zł-7.08 Mil. Molecure's Revenue for the three months ended in Sep. 2025 was zł0.00 Mil. Therefore, Molecure's OCF Margin % for the quarter that ended in Sep. 2025 was 0.00%.

As of today, Molecure's current OCF Yield % is -37.30%.

The historical rank and industry rank for Molecure's OCF Margin % or its related term are showing as below:


During the past 11 years, the highest OCF Margin % of Molecure was 46.72%. The lowest was -236933.33%. And the median was -25592.86%.

WAR:MOC's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Molecure OCF Margin % Related Terms

Molecure OCF Margin % Historical Data

* Premium members only.

The historical data trend for Molecure's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure OCF Margin % Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.72 0.00 0.00 0.00 0.00

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:MOC
29GF Score
Molecure SA WAR:MOC
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Molecure's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-56.99/0
= %

Molecure's OCF Margin for the quarter that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-7.084/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Molecure (WAR:MOC) has a OCF Margin % of 0.00% as of Sep. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Molecure and its competitors. According to the industry distribution chart, Molecure ranks #999999 out of 959 companies in the Biotechnology industry.
Is Molecure's OCF Margin % too high?
Molecure's current OCF Margin % is 0.00%. Based on the distribution chart, Molecure ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecure has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecure ranks #999999 out of 959 companies for OCF Margin %. This places Molecure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Molecure and its competitors. Molecure's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Molecure's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Molecure (WAR:MOC), the current OCF Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
29GF Score

Get the complete analysis for WAR:MOC

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.38
Price